<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05614947</url>
  </required_header>
  <id_info>
    <org_study_id>20-F-16</org_study_id>
    <nct_id>NCT05614947</nct_id>
  </id_info>
  <brief_title>Impact of 60 Days Powdered Tart Cherry Supplementation on Metabolic Syndrome</brief_title>
  <official_title>Impact of 60 Days Powdered Tart Cherry Supplementation on Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metabolic syndrome (MetSyn) is a growing health concern, with up to 25% of the worlds&#xD;
      population having the syndrome. MetSyn is a primary risk factor for cardiovascular disease&#xD;
      and type II diabetes development, and is independently associated with all-cause mortality,&#xD;
      making it an important disease target. The primary treatment for MetSyn is exercise and&#xD;
      weight loss, along with medically necessary treatment. Exercise, along with dietary changes&#xD;
      such as increased fiber and polyphenol intake can positively impact many of the metabolic&#xD;
      abnormalities seen with MetSyn. For example, polyphenols have been shown to decrease lipid&#xD;
      concentration and improved glucose clearance as well as decreased oxidative stress and&#xD;
      inflammation. Powdered tart cherry capsules, which contain the skin of the fruit, provides&#xD;
      polysaccharides (fiber) that would likely act as a substrate for gut bacteria degradation,&#xD;
      providing energy substrates and barrier integrity to the colonocytes and increasing the&#xD;
      bioavailability of the polyphenols to other cells in the body. However there have been no&#xD;
      long-term investigations into the use of powdered tart cherry supplements in MetSyn,&#xD;
      therefore we aim to determine if 60 days tart cherry supplementation modify criteria for&#xD;
      MetSyn in currently diagnosed individuals including body mass, waist circumference, blood&#xD;
      pressure, blood lipid levels and blood glucose control.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 6, 2022</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in baseline systolic and diastolic blood pressure</measure>
    <time_frame>baseline, 60 days post supplmentation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in fasting high-density lipoprotein (HDL) cholesterol</measure>
    <time_frame>baseline, 30 days post supplementation, 60 days post supplmentation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in fasting triglyceride levels</measure>
    <time_frame>baseline, 30 days post supplementation, 60 days post supplmentation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in fasting blood glucose level</measure>
    <time_frame>baseline, 30 days post supplementation, 60 days post supplmentation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in waist circumference</measure>
    <time_frame>baseline, 60 days post supplmentation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in body fat distribution</measure>
    <time_frame>baseline, 60 days post supplmentation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in erythrocyte sedimentation rate</measure>
    <time_frame>baseline, 30 days post supplementation, 60 days post supplmentation</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>tart cherry</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>two capsules daily for 60 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>two capsules daily for 60 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Powdered tart cherry</intervention_name>
    <description>500 mg freeze-dried tart cherry per capsule</description>
    <arm_group_label>tart cherry</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>500 mg colored cornstarch per capsule</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have been diagnosed with metabolic syndrome by a physician or meet the diagnostic&#xD;
             criteria: Waist circumference greater than 40 inches (men) or greater than 35 inches&#xD;
             (women), High blood pressure (greater than 130/80) or taking medication for high blood&#xD;
             pressure, High triglycerides (greater than 150 mg/dL) or low HDL (less than 40 for&#xD;
             men, less than 50 for women), High fasting blood glucose (100-126 mg/dL) or diagnosed&#xD;
             as pre-diabetic&#xD;
&#xD;
          -  Age 25-60&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  currently taking medication for glucose or lipid control, such as metformin and/or&#xD;
             statin&#xD;
&#xD;
          -  currently using anti-inflammatory medications &amp; have not used corticosteroids in the&#xD;
             last two months&#xD;
&#xD;
          -  diagnosed with or currently being treated for an inflammatory condition&#xD;
&#xD;
          -  major organ system impairment (heart failure, renal failure, severe impairment of&#xD;
             respiratory function)&#xD;
&#xD;
          -  currently a smoker or quit less than 12 months ago&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ohio University Exercise Physiology Lab</name>
      <address>
        <city>Athens</city>
        <state>Ohio</state>
        <zip>45701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Hillman, PhD</last_name>
      <phone>740-593-0153</phone>
      <email>hillman@ohio.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 7, 2022</study_first_submitted>
  <study_first_submitted_qc>November 7, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>November 7, 2022</last_update_submitted>
  <last_update_submitted_qc>November 7, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio University</investigator_affiliation>
    <investigator_full_name>Angela Hillman</investigator_full_name>
    <investigator_title>Assistant Professor of Exercise Physiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

